Clinical Trial Update: Study of Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis [Phase 2]

View source ↗

Summary

A Phase 2 dose-effect study of COL-121 ointment in plaque-type psoriasis has completed. The sponsor is Deltanoid Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• COL-121 ointment (COL-121)

Snippet

Sponsor: Deltanoid Pharmaceuticals | Conditions: Plaque-type Psoriasis | Phase 2 | Status: COMPLETED